Aggregation of amyloid-β (Aβ) and tau plays a crucial role in the onset and progression of Alzheimer’s disease (AD). Therefore, the inhibition of Aβ and tau aggregation may represent a potential therapeutic target for AD. Herein, we designed and synthesized both Aβ and tau dual aggregation inhibitors based on the structure of curcumin and developed the novel curcumin derivative PE859. In this study, we investigated the inhibitory activity of PE859 on Aβ aggregationin vitro and the therapeutic effects of PE859 on cognitive dysfunction via dual inhibition of Aβ and tau aggregation in vivo. PE859 inhibited Aβ aggregation in vitro and protected cultured cells from Aβ-induced cytotoxicity. Furthermore, PE859 ameliorated cognitive dysfunction and reduced the amount of aggregated Aβ and tau in brains of senescence-accelerated mouse prone 8 (SAMP8). These results warrant consideration of PE859 as a candidate drug for AD.
MastersCL, MulthaupG, SimmsG, PottgiesserJ, MartinsRN, BeyreutherK (1985) Neuronal origin of a cerebral amyloid: Neurofibrillary tangles of Alzheimer’s disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J4, 2757–2763.
3.
WischikCM, NovakM, ThøgersenHC, EdwardsPC, RunswickMJ, JakesR, WalkerJE, MilsteinC, RothM, KlugA (1988) Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A85, 4506–4510.
JackCR, KnopmanDS, JagustWJ, ShawLM, AisenPS, WeinerMW, PetersenRC, TrojanowskiJQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol9, 119–128.
6.
BatemanRJ, AisenPS, De StrooperB, FoxNC, LemereCA, RingmanJM, SallowayS, SperlingRA, WindischM, XiongC (2011) Autosomal-dominant Alzheimer’s disease: A review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther3, 1.
7.
CorderEH, SaundersM, StrittmatterWJ, SchmechelDE, GaskellPC, SmallGW, RosesD, HainesJL, Pericak-VanceM (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science261, 921–923.
8.
LambertMP, BarlowAK, ChromyBA, EdwardsC, FreedR, LiosatosM, MorganTE, RozovskyI, TrommerB, ViolaKL, WalsP, ZhangC, FinchCE, KrafftGA, KleinWL (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A95, 6448–6453.
9.
DrubinDG, KirschnerMW (1986) Tau protein function in living cells. J Cell Biol103, 2739–2746.
10.
IqbalK, ZaidiT, BancherC, Grundke-IqbalI (1994) Alzheimer paired helical filaments Restoration of the biological activity by dephosphorylation. FEBS Lett349, 104–108.
11.
GongCX, LiuF, Grundke-IqbalI, IqbalK (2005) Post-translational modifications of tau protein in Alzheimer’s disease. J Neural Transm112, 813–838.
12.
BraakH, AlafuzoffI, ArzbergerT, KretzschmanrH, Del TrediciK (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunhistochemistry. Acta Neuropathol112, 389–404.
13.
ArriagadaPV, GrowdonJH, Hedley-WhyteET, HymanBT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology42, 631–639.
14.
BrundenKR, TrojanowskiJQ, LeeVM (2008) Evidence that non-fibrillar tau causes pathology linked to neurodegeneration and behavioral impairments. J Alzheimers Dis14, 393–399.
15.
OkudaM, HijikuroI, FujitaY, WuX, NakayamaS, SakataY, NoguchiY, OgoM, AkasofuS, ItoY, SoedaY, TsuchiyaN, TanakaN, TakahashiT, SugimotoH (2015) PE859, a novel tau aggregation inhibitor, reduces aggregated tau and prevents onset and progression of neural dysfunction In Vivo. PLoS One10, e0117511.
16.
OkudaM, HijikuroI, FujitaY, TeruyaT, KawakamiH, TakahashiT, SugimotoH (2016) Design and synthesis of curcumin derivatives as tau and amyloid β dual aggregation inhibitors. Bioorganic Med Chem Lett26, 5024–5028.
17.
YangF, LimGP, BegumAN, UbedaOJ, SimmonsMR, AmbegaokarSS, ChenP, KayedR, GlabeCG, FrautschySA, ColeGM (2005) Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem280, 5892–5901.
18.
MaQL, ZuoX, YangF, UbedaOJ, GantDJ, AlaverdyanM, TengE, HuS, ChenPP, MaitiP, TeterB, ColeGM, FrautschySA (2013) Curcumin suppresses soluble Tau dinners and corrects molecular chaperone, synaptic, and behavioral deficits in aged human Tau transgenic mice. J Biol Chem288, 4056–4065.
19.
ChandraV, PandavR, DodgeHH, JohnstonJM, BelleSH, DeKoskyST, GanguliM (2001) Incidence of Alzheimer’s disease in a rural community in India: The Indo-US study. Neurology57, 985–989.
20.
BelkacemiA, DogguiS, DaoL, RamassamyC (2011) Challenges associated with curcumin therapy in Alzheimer disease. Expert Rev Mol Med13, e34.
21.
LevineH (1993) Thioflavine T interaction with synthetic Alzheimer’s disease β-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci2, 404–410.
22.
CarusoF, SerizawaT, FurlongDN, OkahataY (1995) Quartz crystal microbalance and surface plasmon resonance study of surfactant adsorption onto gold and chromium oxide surfaces. Langmuir11, 1546–1552.
23.
OkunoH, MoriK, JitsukawaT, InoueH, ChibaS (2006) Convenient method for monitoring Abeta aggregation by quartz-crystal microbalance. Chem Biol Drug Des68, 273–275.
24.
SaharaN, LewisJ, DeTureM, McGowanE, DicksonDW, HuttonM, YenSH (2002) Assembly of tau in transgenic animals expressing P301L tau: Alteration of phosphorylation and solubility. J Neurochem83, 1498–1508.
25.
TakedaT, HosokawaM, TakeshitaS, IrinoM, HiguchiK, MatsushitaT, TomitaY, YasuhiraK, HamamotoH, ShimizuK, IshiiM, YamamuroT (1981) A new murine model of accelerated senescence. Mech Ageing Dev17, 183–194.
26.
MiyamotoM, KiyotaY, YamazakiN, NagaokaA, MatsuoT, NagawaY, TakedaT (1986) Age-related changes in learning and memory in the senescence-accelerated mouse (SAM). Physiol Behav38, 399–406.
27.
YagiH, KatohS, AkiguchiI, TakedaT (1988) Age-related deterioration of ability of acquisition in memory and learning in senescence accelerated mouse: SAM-P/8 as an animal model of disturbances in recent memory. Brain Res474, 86–93.
28.
MorleyJE, KumarVB, BernardoAE, FarrSA, UezuK, TumosaN, FloodJF (2000) β-Amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides21, 1761–1767.
29.
SuredaFX, Gutierrez-CuestaJ, RomeuM, MuleroM, CanudasAM, CaminsA, MallolJ, PallàsM (2006) Changes in oxidative stress parameters and neurodegeneration markers in the brain of the senescence-accelerated mice SAMP-8. Exp Gerontol41, 360–367.
30.
WalshDM, KlyubinI, FadeevaJV, CullenWK, AnwylR, WolfeMS, RowanMJ, SelkoeDJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature416, 535–539.
31.
ClearyJP, WalshDM, HofmeisterJJ, ShankarGM, KuskowskiMA, SelkoeDJ, AsheKH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci8, 79–84.
32.
LesnéS, KohMT, KotilinekL, KayedR, GlabeCG, YangA, GallagherM, AsheKH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature440, 352–357.
RingmanJM, FrautschySA, ColeGM, MastermanDL, CummingsJL (2005) A potential role of the curry spice curcumin in Alzheimer’s disease. Curr Alzheimer Res2, 131–136.
35.
IresonCR, JonesDJ, OrrS, CoughtrieMW, BoocockDJ, WilliamsML, FarmerPB, StewardWP, GescherAJ (2002) Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev11, 105–111.
36.
SharmaOP (1976) Antioxidant activity of curcumin and related compounds. Biochem Pharmacol25, 1811–1812.
37.
Chainani-WuN (2003) Safety and anti-inflammatory activity of curcumin: A comonent of tumeric (Curcuma longa). J Altern Complement Med9, 161–168.
HymanBT, MarzloffK, ArriagadaPV (1993) The lack of accumulation of senile plaques or amyloid burden in Alzheimer’s disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol52, 594–600.
41.
Lasagna-ReevesCA, Castillo-CarranzaDL, SenguptaU, ClosAL, JacksonGR, KayedR (2011) Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener6, 39.
42.
TakashimaA, NoguchiK, MichelG, MerckenM, HoshiM, IshiguroK, ImahoriK (1996) Exposure of rat hippocampal neurons to amyloidβ peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3β. Neurosci Lett203, 33–36.
43.
TomidokoroY, IshiguroK, HarigayaY, MatsubaraE, IkedaM, ParkJM, YasutakeK, KawarabayashiT, OkamotoK, ShojiM (2001) Aβ amyloidosis induces the initial stage of tau accumulation in APPSw mice. Neurosci Lett299, 169–172.
44.
ThalDR, RübU, OrantesM, BraakH (2002) Phases of Ab-deposition in the human brain and its relevance for the development of AD. Neurology58, 1791–1800.
45.
VanaL, KanaanNM, UgwuIC, WuuJ, MufsonEJ, BinderLI (2011) Progression of tau pathology in cholinergic Basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease. Am J Pathol179, 2533–2550.
46.
RapoportM, DawsonHN, BinderLI, VitekMP, FerreiraA (2002) Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A99, 6364–6369.
47.
RobersonED, Scearce-LevieK, PalopJJ, YanF, ChengIH, WuT, GersteinH, YuG-Q, MuckeL (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s Disease Mouse Model. Science316, 750–754.
48.
BaddeleyTC, MccaffreyJ, StoreyJMD, CheungJKS, MelisV, HorsleyD, HarringtonCR, WischikCM (2015) Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer’s disease. J Pharmacol Exp Ther352, 110–118.
49.
DineleyKT, WestermanM, BuiD, BellK, AsheKH, SweattJD (2001) β-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer’s disease. J Neurosci21, 4125–4133.
50.
ShankarGM, BloodgoodBL, TownsendM, WalshDM, SelkoeDJ, SabatiniBL (2007) Natural oligomers of the alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci27, 2866–2875.
51.
Du YanS, ZhuH, FuJ, YanSF, RoherA, TourtellotteWW, RajavashisthT, ChenX, GodmanGC, SternD, SchmidtAM (1997) Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: A proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci U S A94, 5296–5301.
52.
ReddyPH (2006) Amyloid precursor protein-mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer’s disease. J Neurochem96, 1–13.
53.
AisenPS, GauthierS, FerrisSH, SaumierD, HaineD, GarceauD, DuongA, SuhyJ, OhJ, LauWC, SampalisJ (2011) Tramiprosate in mild-to-moderate Alzheimer’s disease - A randomized, double-blind, placebo-controlled, multi-centre study (the alphase study). Arch Med Sci7, 102–111.
54.
Santa-MariaI, HernándezF, Del RioJ, MorenoFJ, AvilaJ (2007) Tramiprosate, a drug of potential interest for the treatment of Alzheimer’s disease, promotes an abnormal aggregation of tau. Mol Neurodegener2, 17.
